At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Verinurad 9 mg+Febuxostat 80 mg +1 moredrug
Likely dose
Verinurad 9 mg + Febuxostat 80 mg orally once dailyAI-extracted
Key inclusion· 4
- ✓Serum uric acid ≥6.0 mg/dL
- ✓eGFR ≥30 mL/min/1.73 m²
- ✓UACR between 30-3500 mg/g (albuminuria range)
- ✓Diagnosed with Type 2 Diabetes
Key exclusion· 4
- ✕Any hyperuricemia drugs (xanthine oxidase inhibitors or URAT1 inhibitors) within 6 months prior to randomization
- ✕Prior gout history, unless prophylaxis therapy is not required
- ✕Pregnant, lactating, or planning to become pregnant
- ✕Unable to undergo MRI assessment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
In Brief
A Phase 2 clinical trial evaluating Verinurad 9 mg+Febuxostat 80 mg and Placebo for Hyperuricemia and 2 related conditions. Completed, enrolled 60 participants across 18 sites.
Detailed Summary
The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperuricemia, Albuminuria, Type 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionAug 2018
TodayJul 2026
First PostedApr 18, 2017
Enrollment StartMay 18, 2017
Primary CompletionAug 13, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.2 years ago
Interventions
Verinurad 9 mg+Febuxostat 80 mgdrug
Capsule administered orally, once daily for 24 weeks
Placebodrug
Capsule administered orally, once daily for 24 weeks